8-K: Cavitation Technologies Agrees to $42M Acquisition by BrightFlixx

Cavitation Technologies, Inc. and Alchemy Beverages Inc. have entered into definitive tender offer agreements with BrightFlixx Finance (Luxembourg) S.A. for an aggregate of $42 million in cash.

Summary

• Cavitation Technologies, Inc. (CVAT) and its 17% owned affiliate, Alchemy Beverages Inc., have entered into new definitive tender offer agreements with BrightFlixx Finance (Luxembourg) S.A.
• These agreements replace prior agreements with European Guarantee Services S. r.l. (EGS), which have been terminated without any termination fees paid.
• BrightFlixx intends to launch cash tender offers for all outstanding shares of CVAT for $35 million and for Alchemy for $7 million, totaling $42 million.
• The offer price for CVAT shares will be $35 million less outstanding liabilities, divided by the total number of shares outstanding at a determined Record Date.
• Similarly, the offer price for Alchemy shares will be $7 million less outstanding liabilities, divided by the total number of Alchemy shares outstanding at its Record Date.
• Key conditions for the CVAT tender offer include the tender of at least 90% of CVAT shares, receipt of regulatory approval (including CFIUS), and the concurrent consummation of the Alchemy tender offer.
• The tender offers have not yet commenced as of the report date.
• The company also disclosed its capitalization, including 323,820,459 outstanding CVAT shares and various warrants and convertible rights.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating progress in a significant transaction, though the offer has not yet commenced and is subject to conditions.

Positives

• Definitive agreements have been signed with BrightFlixx Finance, replacing previous agreements and indicating continued progress towards a transaction.
• The aggregate proposed cash consideration is $42 million ($35 million for CVAT, $7 million for Alchemy).
• The financing institution remains the same, suggesting continuity and potentially expediting the process.
• The termination of prior agreements with EGS occurred without any termination fees.
• CVAT's board has made an initial determination that the transaction is fair and advisable.
• The company has a robust portfolio of 23 issued U.S. patents and several foreign patents related to its hydrodynamic and cavitation technologies, with additional applications pending.
• Licenses for certain technologies have been granted to Alchemy Beverages Inc. and XYRA Corp.

Negatives

• The tender offers have not yet commenced.
• The transaction is subject to significant conditions, including the tender of at least 90% of CVAT shares and regulatory approvals (like CFIUS).
• The final offer price for CVAT shares will be reduced by the company's outstanding liabilities.
• The number of outstanding CVAT shares could increase due to the exercise of warrants and convertible rights, or a private placement, potentially diluting the per-share offer price.
• Alchemy Beverages Inc. has outstanding liabilities of $88,441.81, including convertible debt, which will reduce the net purchase price.
• A pending litigation against Alchemy Beverages Inc. for $30,000, though disputed, represents a potential financial risk.

Risks

• The tender offers may not commence or be completed if the conditions, including the 90% tender threshold and regulatory approvals, are not met.
• The final offer price is subject to adjustment based on the company's liabilities at the Record Date.
• The potential issuance of new shares upon exercise of warrants and convertible rights could dilute the value of the offer for existing shareholders.
• Regulatory approvals, particularly from CFIUS, could delay or prevent the transaction.
• The success of the transaction is contingent on the concurrent consummation of the Alchemy tender offer.
• The company's financial health and ability to meet its obligations could impact the final offer price.

Future Outlook

BrightFlixx Finance (Luxembourg) S.A. expects to commence the tender offers and make the required filings with the SEC. The company will continue to focus on completing the required filings and informing stockholders of advancements in the proposed transactions. The transaction is subject to customary closing conditions, including regulatory approvals and a minimum tender threshold.

Management Comments

• "The execution of these definitive tender offer agreements reflects the continuity of the transaction process," said Neil Voloshin, Chief Executive Officer of CVAT. "The same core transaction participants and financing institution remain involved, and this continuity is intended to help expedite the regulatory and tender-offer process. We remain focused on completing the required filings and keeping our stockholders informed as the proposed transactions advance."
• Dr. Kassem Lahham added: "We are pleased that BrightFlixx Finance (Luxembourg) S.A. is moving forward with the new definitive agreements with Cavitation Technologies and Alchemy. The same core participants and financing institution remain associated with the transaction, which is intended to help expedite the process. BrightFlixx Finance (Luxembourg) S.A. looks forward to working constructively with the companies and their advisers to advance the proposed all-cash tender offers in accordance with the definitive purchase agreements and applicable regulatory requirements."

Industry Context

StockSavvy.ai notes that this transaction aligns with a broader trend of consolidation in the nanotechnology and sustainable solutions sectors, where companies with specialized intellectual property are often targets for acquisition by larger entities seeking to expand their technological capabilities or market reach.

Comparison to Industry Standards

• The tender offer structure is a common method for acquiring publicly traded companies, aiming for a high percentage of shareholder participation.
• The condition requiring 90% tender for CVAT is a high threshold, often seen in transactions where the acquirer seeks significant control or to facilitate a subsequent merger or squeeze-out.
• The involvement of CFIUS indicates that the transaction involves foreign investment and is subject to national security review, a standard procedure for such deals.
• The valuation of CVAT at $35 million (less liabilities) and Alchemy at $7 million (less liabilities) will be compared against industry benchmarks for nanotechnology and beverage technology companies, respectively, once more financial details are disclosed.

Legal Proceedings

• In Verb Technology, Inc. v. Alchemy Beverages Inc., a civil case pending in Delaware state court, the plaintiff is asserting a claim for $30,000 in compensation for media services under a contract. Alchemy is disputing the claim and holds breach of contract claims against the plaintiff.

Related Party Transactions

• Cavitation Technologies, Inc. holds a 17% equity stake in Alchemy Beverages Inc.
• On May 20, 2025, 5,000,000 CVAT shares were issued to Union Consulting Limited for services related to introducing Company and Buyer for the Transaction.

Stakeholder Impact

• Shareholders of Cavitation Technologies, Inc. will have the opportunity to tender their shares for cash, subject to the final offer price and tender conditions.
• Shareholders of Alchemy Beverages Inc. will have the opportunity to tender their shares for cash, subject to the final offer price and tender conditions.
• The transaction may impact employees of Cavitation Technologies and Alchemy, though no specific details on workforce changes are provided.
• Creditors of Cavitation Technologies and Alchemy will be affected by the settlement of outstanding liabilities as part of the transaction.

Next Steps

• BrightFlixx Finance (Luxembourg) S.A. is expected to commence the tender offers.
• Tender Offer Statements on Schedule TO will be filed with the SEC.
• Cavitation Technologies, Inc. will file a Solicitation/Recommendation Statement on Schedule 14D-9.
• Shareholders and investors should read the tender offer documents and Schedule 14D-9 when available.
• The transaction is subject to satisfaction or waiver of certain conditions, including regulatory approvals and a minimum tender of 90% of CVAT shares.

Key Dates

Recommendation

The announcement of definitive agreements for an acquisition is positive, but the offer has not commenced and is subject to significant conditions, including a high tender threshold (90%) and regulatory approvals. The final offer price is also subject to adjustment based on liabilities. Therefore, while progress has been made, the outcome remains uncertain, warranting a 'hold' recommendation until the tender offer commences and conditions are closer to being met.

Keywords

Cavitation Technologies, BrightFlixx Finance, Tender Offer, Acquisition, Alchemy Beverages, Nanotechnology, Corporate Finance, Merger